| 翻訳と辞書 |
| Marcel R.M. van den Brink ： ウィキペディア英語版 |
Marcel R.M. van den Brink
Marcel R.M. van den Brink (Oegstgeest, Netherlands on November 14, 1960) is a Dutch hematologist and researcher who is an expert in hematopoietic stem cell transplantation for cancer patients. He is Head of the Division of Hematologic Oncology, Alan Houghton Chair in Immunology, Attending Physician on the Adult Bone Marrow Transplantation Service, and Member at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, New York. He holds joint appointments in Sloan-Kettering Institute's Immunology Program, the Department of Medicine at MSKCC, and is also Professor of Medicine and Immunology at Weill Cornell Graduate School of Medical Sciences.
As a physician-scientist, van den Brink studies allogeneic bone marrow transplantation both in the clinic and the laboratory. Major contributions include a) the development of strategies to enhance post-transplant immune reconstitution〔("Immune Reconstitution" ), "Sloan Kettering Institute, Immunology Program"〕 such as Interleukin-7,〔Stallard, Jim, ("New Treatment May Help Transplant Patients Recover Immune Function More Quickly" ), "On Cancer, News and Insights from Memorial Sloan Kettering", December 21, 2012〕 Keratinocyte Growth Factor, Sex Steroid Blockade, Interleukin-22 (IL-22), and adoptive cell therapy with precursor T cells〔Kiesler, E., (" Study Points the Way for Future Therapy to Revive a Damaged Immune System" ), "On Cancer, News and Insights from Memorial Sloan Kettering", April 6, 2012.〕〔Grisham, J., ("Researchers Show Therapy Could Improve Stem Cell Transplants" ), On Cancer, News and Insights from Memorial Sloan Kettering", December 12, 2011.〕 and b) novel insights in the pathophysiology of graft-versus-host disease (GVHD)〔("Graft-versus-host Disease" ), "Sloan Kettering Institute, Immunology Program"〕 such as the role of T cell cytolytic pathways, intestinal homing molecules, donor-derived neovascularization, and more recently, intestinal microflora〔Grishman, J., ("Microbiome Studies May Benefit Cancer Patients" ), On Cancer, News and Insights from Memorial Sloan Kettering", August 7, 2013〕〔Grisham, J., ("Two Memorial Sloan Kettering Studies Focus on Role of Antibiotics in Stem Cell Transplantation" ), On Cancer, News and Insights from Memorial Sloan Kettering", July 19, 2012.〕
== Biography ==
Van den Brink obtained his M.D. and Ph.D. cum laude from the University of Leiden in the Netherlands. He completed a postdoctoral fellowship at The University of Pittsburgh Cancer Institute in Pittsburgh, Pennsylvania, and then completed an internship and residency at Duke University Medical Center in Durham, North Carolina. From 1994-1997, van den Brink was a Clinical Fellow in Hematology and Oncology at Beth Israel Deaconess Medical Center and a Clinical Fellow in Medicine at Harvard Medical School in Boston, Massachusetts. He completed a post-doctoral fellowship with Dr. Steven J. Burakoff, MD at the Dana-Farber Cancer Institute in Boston, MA from 1995-1999.〔("NYSTEM, New York State Stem Cell Science: Marcel R.M. van den Brink" )〕
In 1999, van den Brink joined the Adult Allogeneic Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center and the Immunology Program at Sloan-Kettering Institute. He was jointly appointed at Weill Cornell Medical College in 2000. He then served as Chief of the Adult Allogeneic Bone Marrow Transplantation Service from 2004-2008〔Rieff, D.("Illness as More Than Metaphor" ), "The New York Times Magazine", December 4, 2005.〕 In 2008, van den Brink was named Head of the Division of Hematologic Oncology.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Marcel R.M. van den Brink」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|